New York, May 30, 2026, 18:02 EDT
Philip Morris International Inc. ended the shortened trading week at $177.38, slipping 0.67% Friday and down 6.14% over the last five sessions. Shares of the Marlboro maker outside the U.S. remain well under the May 19 high of $193.05. The New York Stock Exchange was closed Saturday and for Memorial Day on Monday, May 25.
The pullback came even as the rest of the market held up. The S&P 500 gained 0.2% Friday to close at 7,580.06, booking its ninth weekly advance in a row. The Dow Jones Industrial Average was up 0.7% to 51,032.46, Associated Press market data showed.
Next week, attention turns to Philip Morris. CEO Jacek Olczak is set to answer questions at Deutsche Bank’s dbAccess Global Consumer Conference on Tuesday, June 2, at 11:15 a.m. CEST, or 5:15 a.m. ET.
Investors want more detail on Zyn nicotine pouches and IQOS heated-tobacco devices as Philip Morris shifts its focus from cigarettes. Smoke-free products, which include heated tobacco, nicotine pouches and e-vapor, accounted for 43% of the company’s first-quarter net revenue.
Regulation is the next driver. This week, Reuters said the U.S. Food and Drug Administration has started using “enforcement discretion”—choosing not to apply certain rules while it reviews applications—which might open the door for more nicotine products to hit shelves. Barclays analyst Pallav Mittal said this could “catalyse sales” and estimated Philip Morris might move up to 12 million extra Zyn pouches this year if a new version rolls out. MarketScreener
Bullish bets count on that. The tougher question is whether Zyn can pick up growth again without cutting prices.
Philip Morris lowered its full-year adjusted EPS target in April to $8.36-$8.51, blaming regulation and rivals. Adjusted EPS is profit per share minus some items. At the time, Jefferies analyst Andrei Andon-Ionita told Reuters that Zyn volumes were still weak, saying the “continued momentum loss” could help British American Tobacco’s Velo. Reuters
Philip Morris posted adjusted diluted EPS of $1.96 for the first quarter, a 16% rise, on net revenue of $10.15 billion. CEO Olczak said results “exceeded our expectations,” with IQOS driving the gain. Philip Morris International
Philip Morris got IQOS onto Kantar’s BrandZ 2026 top 100 list at No. 74 last week, drawing more attention to the brand. Oggie Kapetanovic, president of heat-not-burn products, called it a “powerful validation” for IQOS. The company said IQOS now has over 35 million users worldwide. Stock Titan
Other tobacco names saw losses as well. Altria Group dropped 3.32% Friday to $69.58, while British American Tobacco’s U.S. shares slipped 1.80% to $61.79. So the move wasn’t just about Philip Morris, although Zyn and IQOS still stand out as big issues for the stock.
The risk is big, though. Former FDA tobacco chief Mitch Zeller told Reuters the policy could mean adult smokers get untested products that turn out risky or not much good for quitting. If regulators backtrack, if worries about youth use rise, or if Velo and other players push prices lower, the Zyn bounce could fade fast.
Wall Street isn’t all in on the stock. Jefferies lifted its price target for Philip Morris to $180 from $175 on May 27, but left its Hold rating unchanged, MT Newswires reported. The shares finished Friday just under that target. On Tuesday, the CEO’s appearance may need more than general comments about smoke-free growth to calm the stock.
Philip Morris is set to report its second-quarter results on Wednesday, July 22, at 9:00 a.m. EDT. The next full earnings reset is still weeks off, so next week is about the webcast, regulatory headlines, and whether buyers return after the drop in the short week.
